Panacea Life Sciences Holdings

PLSH

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$0.09

+0.01 (+11.93%)

Market Cap

$2.0M

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Mixed

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+233.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 17.8M (2021) → 59.5M (2025)

Winston Score History

The full picture

Panacea Life Sciences Holdings is a small U.S. company that makes hemp-derived CBD products. Its lineup includes oils, capsules, topicals, and pet products sold mainly to everyday consumers through its website and select retail channels. The company operates in the specialty health and wellness space, competing in a crowded market alongside hundreds of other CBD brands.

Panacea earns revenue primarily through direct-to-consumer online sales and some wholesale distribution. It is a very small company based in Colorado with a market cap near zero and has consistently lost money, as reflected in deeply negative margins. The CBD industry faces serious headwinds including unclear federal regulation from the FDA, intense price competition, and difficulty gaining shelf space at major retailers — all of which pose significant challenges to Panacea reaching profitability.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-78.8% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-125.1% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

52.3%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~8 years

$824,545 cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

$824,545 cash & investments at current burn rate

Revenue declining

Panacea Life Sciences Holdings's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

99.0%

Premium pricing power — 99.0% gross margin

Profit after running costs

Operating Margin

-153.6%

Losing money on operations — -153.6%

Return on the money invested

ROCE

-59.4%

Weak — -59.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-90.2%

Shrinking sales (-90.2% YoY)

Profit growth

EPS YoY

-166.4%

Earnings shrinking (-166.4% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

173.9%

Converts sales into free cash efficiently (173.9%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.17

Conservative — low debt load (0.17)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial